Is UFPT a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for UFP Technologies, Inc. (UFPT) rests on The Intuitive Surgical contract, now written through 2029: Intuitive Surgical SARL is named in the filings as UFP's largest customer, and in February 2026 the two signed Amendment No. The bear case rests on customer concentration is the first-order risk: two customers accounted for approximately ~24.3% and ~21.5% of 2025 net sales, and the company's own risk factors flag the possibility that Intuitive Surgical could decide to manufacture the products itself or through another supplier. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

UFP Technologies, Inc. is a contract development and manufacturing organization headquartered in Newburyport, Massachusetts, incorporated in Delaware in 1993 and listed on Nasdaq as UFPT. It engineers and manufactures single-use and single-patient medical devices, components and packaging that customers sell under their own labels: protective drapes for robotic surgery, surgical and endoscopic disposables, advanced wound care and infection prevention products, packaging for orthopedic implants, cardiac implant components and catheter dispenser coils. The work runs through die cutting, molding, thermoforming, welding and lamination under trademarks including UFP MEDTECH, FLEXSHIELD and BIOSHELL. The company had ~4,846 full-time employees as of January 2026, up from ~4,146 a year earlier, across plants in the United States, Puerto Rico, the Dominican Republic, Mexico, Ireland and Costa Rica; nineteen sites are ISO 13485 certified and thirteen are FDA registered. Medical customers supplied ~92.1% of 2025 net sales. The financial picture is a steady grower that the market has repriced sharply in both directions. Full-year 2025 revenue reached ~$603 million, up ~19.5% from ~$504 million in 2024, and the trailing twelve months through June 2026 stand at ~$632 million with ~$72 million of net income and diluted earnings per share of ~$9.25. The June 2026 quarter was a record on all three measures: revenue of ~$174.0 million (up ~15.1%, ~12.4% organic), net income of ~$20.9 million, and GAAP earnings per share of ~$2.68 against adjusted earnings per share of ~$2.92. Gross margin improved to ~29.3% from ~28.8%. At roughly ~33 times trailing earnings and a ~$2.36 billion market value, after a twelve-month band of about ~$174 to ~$339, the central question is whether a business with ~46% of sales in two accounts and a large production transfer still working through its costs deserves that multiple.

The bull case for UFPT

1. The Intuitive Surgical contract, now written through 2029

Intuitive Surgical SARL is named in the filings as UFP's largest customer, and in February 2026 the two signed Amendment No. 27 to a manufacturing supply agreement first struck in 2014. The amendment extends the term by two years through December 31, 2029, materially increases annual minimum volumes on the largest program for 2028 and 2029, adds another program, and sets volume-based pricing with cost-sharing provisions. That converts a concentration risk into contracted visibility for several years, at the price of volume-based pricing concessions.

2. Shifting production to the Dominican Republic and Mexico

UFP has been building out plants in La Romana and Santiago in the Dominican Republic and in Tijuana, Mexico, with the stated aim of adding capacity and lowering its cost structure over time. Management said in August 2026 that the early operational benefits are showing up but that full realization is taking longer than anticipated, and that the transition is creating near-term mix and margin pressure inside the US operations. Gross margin still rose to ~29.3% in the June quarter, so the drag has so far been absorbed.

3. Growth is broadening past the biggest accounts

In the June 2026 quarter the top five customers grew ~14.7% while the rest of the MedTech business grew ~19.7%, the pattern that would eventually dilute concentration if it holds. Management attributed the increase to the Surfaces and Support, Cardiovascular, Infection Control and Orthopedics sub-markets. Non-medical sales were flat at under ~8% of the total, so almost all incremental revenue now comes from medical programs.

4. Bolt-on acquisitions funded by a deleveraging balance sheet

The platform was assembled through repeated small purchases, including AJR Specialty and AJR Custom Foam for ~$2.8 million in April 2025 and Universal Plastics & Engineering for ~$7.5 million in July 2025, alongside larger 2024 deals. Long-term debt fell to ~$117 million by June 2026 at a weighted average rate near ~5.0%, under a ~$275 million facility that runs to June 2029 and leaves revolver capacity for further deals. The company pays no dividend, retaining earnings for operations and further acquisitions.

The bear case for UFPT

Customer concentration is the first-order risk: two customers accounted for approximately ~24.3% and ~21.5% of 2025 net sales, and the company's own risk factors flag the possibility that Intuitive Surgical could decide to manufacture the products itself or through another supplier. A cybersecurity incident detected on or about February 14, 2026 disrupted systems including billing and label making, and certain company data appears to have been stolen or destroyed; UFP expects most direct costs to be recovered through insurance, but has disclosed that litigation, regulatory investigations or enforcement actions remain possible outcomes. The Dominican Republic facilities are described in the filings as crucial to operations, and the company specifically names civil unrest in nearby Haiti and natural disaster exposure among its concerns. Cash conversion was weak in the first half of 2026, with ~$18.8 million of operating cash flow against ~$38.3 million of net income as receivables rose ~$30.5 million. The stock also carries roughly ~33 times trailing earnings after a twelve-month range of about ~$174 to ~$339, so the multiple has historically moved a great deal on modest changes in the growth rate.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding UFPT already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on UFPT

Too few analysts publish on UFPT for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The UFPT forecast page covers what coverage does exist.

How is UFPT valued? (as of August 2026)

Price

$304.21

Market cap

$2.36B

P/E (TTM)

33.03

Forward P/E

25.62

Price / book

5.10

Beta

1.06

52-week range

$173.86 to $338.71

Snapshot for UFPT as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$632M
FY2025 revenue: ~$603M (up ~19.5% YoY)
Q2 2026 revenue: ~$174.0M (up ~15.1% YoY, ~12.4% organic)
Net income (TTM): ~$72M, diluted EPS ~$9.25
Gross margin (Q2 2026): ~29.3%, up from ~28.8%
Long-term debt: ~$117M at ~5.0% weighted average rate

At about ~$304 per share on ~7.75 million shares outstanding, UFPT carries a market value near ~$2.36 billion, which is roughly ~33 times trailing earnings and roughly ~3.7 times trailing revenue. That is a premium to most contract manufacturers, reflecting the medical mix, the ~29% gross margin and a multi-year record of double-digit growth. The balance sheet is light, with ~$117 million of long-term debt against a ~$275 million facility maturing in June 2029.

How do you decide if UFPT is a buy?

Rather than asking whether UFPT is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold UFPT indirectly through an index or sector ETF before adding more.

What would change your mind on UFPT

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: The Intuitive Surgical contract, now written through 2029 stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: customer concentration is the first-order risk: two customers accounted for approximately ~24.3% and ~21.5% of 2025 net sales, and the company's own risk factors flag the possibility that Intuitive Surgical could decide to manufacture the products itself or through another supplier fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the UFPT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about UFPT against your real portfolio and see your actual exposure before deciding.

Investing in UFP Technologies, Inc. with AI

Connect the broker you already use and ask Walnut's AI how UFPT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does UFPT fit me?

FAQ

Is UFPT a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on The Intuitive Surgical contract, now written through 2029, with revenue (ttm) at ~$632M. The bear case rests on customer concentration is the first-order risk: two customers accounted for approximately ~24.3% and ~21.5% of 2025 net sales, and the company's own risk factors flag the possibility that Intuitive Surgical could decide to manufacture the products itself or through another supplier. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell UFPT?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Customer concentration is the first-order risk: two customers accounted for approximately ~24.3% and ~21.5% of 2025 net sales, and the company's own risk factors flag the possibility that Intuitive Surgical could decide to manufacture the products itself or through another supplier. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

What is the bull case for UFPT?

The Intuitive Surgical contract, now written through 2029. Intuitive Surgical SARL is named in the filings as UFP's largest customer, and in February 2026 the two signed Amendment No.

What is the bear case for UFPT?

What does UFP Technologies, Inc. do?

Contract manufacturer of single-use medical devices, components and sterile packaging built for other companies' brands.

What would have to change for UFPT to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The Intuitive Surgical contract, now written through 2029) stalling in the reported numbers rather than in the narrative, the risk above (customer concentration is the first-order risk: two customers accounted for approximately ~24.3% and ~21.5% of 2025 net sales, and the company's own risk factors flag the possibility that Intuitive Surgical could decide to manufacture the products itself or through another supplier) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does UFP Technologies actually make?

It makes single-use and single-patient medical devices, components and sterile packaging to other companies' specifications. Examples given in its filings include protective drapes for robotic surgery, disposables for surgical and endoscopic procedures, advanced wound care products, packaging for orthopedic implants, components for cardiac implants and dispenser coils for catheters. Almost none of it carries the UFP name at the point of care, because the customer's brand goes on the finished product.

Is UFPT the same company as UFPI?

No. UFP Technologies (Nasdaq: UFPT) is a Massachusetts-based medical device contract manufacturer with ~$632 million in trailing revenue. UFP Industries (Nasdaq: UFPI) is a Michigan-based wood and building products company that is several times larger. The tickers and names look alike, the businesses have nothing to do with each other, and they are frequently confused in screeners and news feeds.

Who are UFP Technologies' largest customers?

For the year ended December 31, 2025, two customers accounted for approximately ~24.3% and ~21.5% of net sales, with no other customer above 10%. The filings identify Intuitive Surgical SARL, the robotic surgery company, as the largest of the two. In February 2026 UFP extended its manufacturing supply agreement with Intuitive through the end of 2029 and raised the minimum annual volumes on its largest program for 2028 and 2029.

Walnut is informational, not investment advice, and gives no verdict on UFPT. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.